Dan Linda Wang

US Patent:

20230089490, Mar 23, 2023

Filed:

Oct 9, 2020

Appl. No.:

17/767727

Inventors:

- Boston MA, US
Craig Mendonca - Shrewsbury MA, US
Dan Wang - Belchertown MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

C12N 15/113
C12N 15/86
A61K 48/00
A61P 7/00
A61P 11/00
A61P 21/00

Abstract:

Aspects of the disclosure relate to compositions and methods for treating certain diseases associated with the presence of one or more premature stop codons in a gene, for example dominantly inherited diseases or recessively inherited diseases. In some embodiments, compositions comprise a vector (e.g., a viral vector, such as an rAAV vector) encoding one or more synthetic suppressor transfer RNAs (tRNAs) configured to read-through certain stop codons (e.g., premature stop codons). In some embodiments, the disclosure relates to methods for treating Hurler syndrome comprising administering such vectors to a subject.

US Patent:

20210023241, Jan 28, 2021

Filed:

Mar 22, 2019

Appl. No.:

16/982640

Inventors:

- Boston MA, US
Guangqing Gao - Westborough MA, US
Jun Xie - Shrewsbury MA, US
Jung Min Kim - Worcester MA, US
Dan Wang - Belchertown MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 48/00
C07K 14/635
A61P 19/10
C12N 15/86
C07K 14/005
C12N 15/113

Abstract:

In some aspects, the disclosure relates to compositions and methods for modulating (e.g., increasing and/or decreasing) bone mass in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vectors such as rAAV vectors, configured to express transgenes that promote (e.g., increase) or inhibit (e.g., decrease) activity, differentiation, or function of certain types of bone cells, for example osteoblasts, osteoclasts, osteocytes, etc. In some embodiments, the isolated nucleic acids and vectors described by the disclosure are useful for treating disorders and conditions associated with increased bone mass (e.g., osteopetrosis) or decreased bone mass (e.g., osteoporosis).

US Patent:

20200231953, Jul 23, 2020

Filed:

Jan 29, 2020

Appl. No.:

16/775311

Inventors:

- Boston MA, US
Phillip D. Zamore - Northborough MA, US
Dan Wang - Belchertown MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

C12N 9/22
A61K 48/00
C12N 15/90
C07K 14/005
C12N 7/00
C12N 15/11

Abstract:

The disclosure in some aspects relates to recombinant adeno-associated viruses having nuclease grafted to one or more capsid proteins. In some aspects, the disclosure relates to isolated AA V capsid proteins having terminally grafted nucleases and isolated nucleic acids encoding the same. Recent approaches to delivering nucleases to cells for gene editing have focused on delivering of expression vectors engineered to express the nucleases in target cells. However, these approaches have proved to be problematic in many instances due to genotoxicity resulting from to prolonged expression of gene editing system in vivo. To prevent such off-target genotoxicity due to prolonged presence of a gene editing system, several studies explored delivery of mRNA or protein instead of delivering the gene coding for the nucleases in cell culture.

US Patent:

20200181646, Jun 11, 2020

Filed:

Jun 6, 2018

Appl. No.:

16/619733

Inventors:

- Boston MA, US
Guangping GAO - Westborough MA, US
Michael R. GREEN - Boylston MA, US
Dan WANG - Belchertown MA, US
Tessa Mercedes SIMONE - Worcester MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

C12N 15/86
C07K 14/47

Abstract:

In some aspects, the disclosure relates to compositions and methods of engineering a transgene. In some embodiments, the disclosure provides self-regulating recombinant nucleic acids, viral vectors and pharmaceutical compositions comprising a MeCP2 transgene. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases and disorders associated with a loss of function mutation, for example Rett syndrome.

US Patent:

20180179501, Jun 28, 2018

Filed:

Feb 12, 2016

Appl. No.:

15/550452

Inventors:

- Boston MA, US
Phillip D. Zamore - Northborough MA, US
Dan Wang - Belchertown MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

C12N 9/22
C07K 14/005
C12N 7/00
C12N 15/11
C12N 15/90
A61K 48/00

Abstract:

The disclosure in some aspects relates to recombinant adeno-associated viruses having nuclease grafted to one or more capsid proteins. In some aspects, the disclosure relates to isolated AAV capsid proteins having terminally grafted nucleases and isolated nucleic acids encoding the same. Recent approaches to delivering nucleases to cells for gene editing have focused on delivering of expression vectors engineered to express the nucleases in target cells. However, these approaches have proved to be problematic in many instances due to genotoxicity resulting from to prolonged expression of gene editing system in vivo. To prevent such off-target genotoxicity due to prolonged presence of a gene editing system, several studies explored delivery of mRNA or protein instead of delivering the gene coding for the nucleases in cell culture.